Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEM201
- Development stage
- Unknown
- Lead developer
- DEM Biopharma
- Modality
- Antibody-Based Therapeutics
01
Overview
DEM201: sourced facts only. name: "DEM201 was selected as a clinical candidate and is specific for human SMAGP with sub-nanomolar (nM) affinity." [DOI:10.1158/1538-7445.am2025-4254]; target: "DEM201 was selected as a clinical candidate and is specific for human SMAGP with sub-nanomolar (nM) affinity." [DOI:10.1158/1538-7445.am2025-4254]; developer: "DEM BioPharma, Inc., Cambridge, MA." [DOI:10.1158/1538-7445.am2025-4254]; modality: "Development of DEM201, a blocking antibody against SMAGP, a novel “Don′t Eat Me” signal overexpressed in cancer" [DOI:10.1158/1538-7445.am2025-4254]; stage: "In vivo, DEM201 significantly inhibited the growth of SMAGP-expressing RKO tumor xenografts." [DOI:10.1158/1538-7445.am2025-4254]
02
Targets
SMAGP (Small cell adhesion glycoprotein)
Beyond the preview
Go deeper on DEM201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEM201.